-
A Large Open Access Dataset of Brain Metastasis 3D Segmentations with Clinical and Imaging Feature Information
Authors:
Divya Ramakrishnan,
Leon Jekel,
Saahil Chadha,
Anastasia Janas,
Harrison Moy,
Nazanin Maleki,
Matthew Sala,
Manpreet Kaur,
Gabriel Cassinelli Petersen,
Sara Merkaj,
Marc von Reppert,
Ujjwal Baid,
Spyridon Bakas,
Claudia Kirsch,
Melissa Davis,
Khaled Bousabarah,
Wolfgang Holler,
MingDe Lin,
Malte Westerhoff,
Sanjay Aneja,
Fatima Memon,
Mariam S. Aboian
Abstract:
Resection and whole brain radiotherapy (WBRT) are the standards of care for the treatment of patients with brain metastases (BM) but are often associated with cognitive side effects. Stereotactic radiosurgery (SRS) involves a more targeted treatment approach and has been shown to avoid the side effects associated with WBRT. However, SRS requires precise identification and delineation of BM. While…
▽ More
Resection and whole brain radiotherapy (WBRT) are the standards of care for the treatment of patients with brain metastases (BM) but are often associated with cognitive side effects. Stereotactic radiosurgery (SRS) involves a more targeted treatment approach and has been shown to avoid the side effects associated with WBRT. However, SRS requires precise identification and delineation of BM. While many AI algorithms have been developed for this purpose, their clinical adoption has been limited due to poor model performance in the clinical setting. Major reasons for non-generalizable algorithms are the limitations in the datasets used for training the AI network. The purpose of this study was to create a large, heterogenous, annotated BM dataset for training and validation of AI models to improve generalizability. We present a BM dataset of 200 patients with pretreatment T1, T1 post-contrast, T2, and FLAIR MR images. The dataset includes contrast-enhancing and necrotic 3D segmentations on T1 post-contrast and whole tumor (including peritumoral edema) 3D segmentations on FLAIR. Our dataset contains 975 contrast-enhancing lesions, many of which are sub centimeter, along with clinical and imaging feature information. We used a streamlined approach to database-building leveraging a PACS-integrated segmentation workflow.
△ Less
Submitted 11 September, 2023; v1 submitted 10 September, 2023;
originally announced September 2023.
-
The Brain Tumor Segmentation (BraTS-METS) Challenge 2023: Brain Metastasis Segmentation on Pre-treatment MRI
Authors:
Ahmed W. Moawad,
Anastasia Janas,
Ujjwal Baid,
Divya Ramakrishnan,
Rachit Saluja,
Nader Ashraf,
Leon Jekel,
Raisa Amiruddin,
Maruf Adewole,
Jake Albrecht,
Udunna Anazodo,
Sanjay Aneja,
Syed Muhammad Anwar,
Timothy Bergquist,
Evan Calabrese,
Veronica Chiang,
Verena Chung,
Gian Marco Marco Conte,
Farouk Dako,
James Eddy,
Ivan Ezhov,
Ariana Familiar,
Keyvan Farahani,
Juan Eugenio Iglesias,
Zhifan Jiang
, et al. (206 additional authors not shown)
Abstract:
The translation of AI-generated brain metastases (BM) segmentation into clinical practice relies heavily on diverse, high-quality annotated medical imaging datasets. The BraTS-METS 2023 challenge has gained momentum for testing and benchmarking algorithms using rigorously annotated internationally compiled real-world datasets. This study presents the results of the segmentation challenge and chara…
▽ More
The translation of AI-generated brain metastases (BM) segmentation into clinical practice relies heavily on diverse, high-quality annotated medical imaging datasets. The BraTS-METS 2023 challenge has gained momentum for testing and benchmarking algorithms using rigorously annotated internationally compiled real-world datasets. This study presents the results of the segmentation challenge and characterizes the challenging cases that impacted the performance of the winning algorithms. Untreated brain metastases on standard anatomic MRI sequences (T1, T2, FLAIR, T1PG) from eight contributed international datasets were annotated in stepwise method: published UNET algorithms, student, neuroradiologist, final approver neuroradiologist. Segmentations were ranked based on lesion-wise Dice and Hausdorff distance (HD95) scores. False positives (FP) and false negatives (FN) were rigorously penalized, receiving a score of 0 for Dice and a fixed penalty of 374 for HD95. Eight datasets comprising 1303 studies were annotated, with 402 studies (3076 lesions) released on Synapse as publicly available datasets to challenge competitors. Additionally, 31 studies (139 lesions) were held out for validation, and 59 studies (218 lesions) were used for testing. Segmentation accuracy was measured as rank across subjects, with the winning team achieving a LesionWise mean score of 7.9. Common errors among the leading teams included false negatives for small lesions and misregistration of masks in space.The BraTS-METS 2023 challenge successfully curated well-annotated, diverse datasets and identified common errors, facilitating the translation of BM segmentation across varied clinical environments and providing personalized volumetric reports to patients undergoing BM treatment.
△ Less
Submitted 17 June, 2024; v1 submitted 1 June, 2023;
originally announced June 2023.
-
The Brain Tumor Segmentation (BraTS) Challenge 2023: Focus on Pediatrics (CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs)
Authors:
Anahita Fathi Kazerooni,
Nastaran Khalili,
Xinyang Liu,
Debanjan Haldar,
Zhifan Jiang,
Syed Muhammed Anwar,
Jake Albrecht,
Maruf Adewole,
Udunna Anazodo,
Hannah Anderson,
Sina Bagheri,
Ujjwal Baid,
Timothy Bergquist,
Austin J. Borja,
Evan Calabrese,
Verena Chung,
Gian-Marco Conte,
Farouk Dako,
James Eddy,
Ivan Ezhov,
Ariana Familiar,
Keyvan Farahani,
Shuvanjan Haldar,
Juan Eugenio Iglesias,
Anastasia Janas
, et al. (48 additional authors not shown)
Abstract:
Pediatric tumors of the central nervous system are the most common cause of cancer-related death in children. The five-year survival rate for high-grade gliomas in children is less than 20\%. Due to their rarity, the diagnosis of these entities is often delayed, their treatment is mainly based on historic treatment concepts, and clinical trials require multi-institutional collaborations. The MICCA…
▽ More
Pediatric tumors of the central nervous system are the most common cause of cancer-related death in children. The five-year survival rate for high-grade gliomas in children is less than 20\%. Due to their rarity, the diagnosis of these entities is often delayed, their treatment is mainly based on historic treatment concepts, and clinical trials require multi-institutional collaborations. The MICCAI Brain Tumor Segmentation (BraTS) Challenge is a landmark community benchmark event with a successful history of 12 years of resource creation for the segmentation and analysis of adult glioma. Here we present the CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs 2023 challenge, which represents the first BraTS challenge focused on pediatric brain tumors with data acquired across multiple international consortia dedicated to pediatric neuro-oncology and clinical trials. The BraTS-PEDs 2023 challenge focuses on benchmarking the development of volumentric segmentation algorithms for pediatric brain glioma through standardized quantitative performance evaluation metrics utilized across the BraTS 2023 cluster of challenges. Models gaining knowledge from the BraTS-PEDs multi-parametric structural MRI (mpMRI) training data will be evaluated on separate validation and unseen test mpMRI dataof high-grade pediatric glioma. The CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs 2023 challenge brings together clinicians and AI/imaging scientists to lead to faster development of automated segmentation techniques that could benefit clinical trials, and ultimately the care of children with brain tumors.
△ Less
Submitted 23 May, 2024; v1 submitted 26 May, 2023;
originally announced May 2023.